125 patents
Page 5 of 7
Utility
High purity oritavancin and method of producing same
14 Dec 20
Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
Filed: 10 Jun 19
Utility
Automatic injection device
7 Dec 20
A syringe carrier for use within an automatic injection device includes a substantially tubular body having a first end, a middle portion, and a second end, configured to contain a portion of a syringe and displace the syringe within a housing of the automatic injection device from a first position to a second position; a first pair of legs defining at least a portion of a front opening in the substantially tubular body proximal to the first end; a second pair of legs defining at least a portion of a rear opening in the substantially tubular body proximal to the first end; and a syringe carrier coupler having a first beam and a second beam extending from the middle portion partially beyond the first pair of legs at the first end of the substantially tubular body.
Sherwin S. Shang, Joseph F. Julian, Chuan Li, Eduard N. Tsvirko, Edwin Chim, Shubha Chethan Somashekar, Esra Ozdaryal
Filed: 24 May 18
Utility
Protein tyrosine phosphatase inhibitors and methods of use thereof
30 Nov 20
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym
Filed: 3 Jun 20
Utility
Anti-CD40 antibody
23 Nov 20
The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
Filed: 2 Sep 19
Utility
Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
16 Nov 20
The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
Wilfried Braje, Katarina Britze, Justin D. Dietrich, Anais Jolit, Johannes Kaschel, Johanna Klee, Tanja Lindner
Filed: 13 Jan 20
Utility
Modulators of the integrated stress pathway
16 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
Filed: 4 May 17
Utility
Anti-PTK7 antibodies and methods of use
16 Nov 20
Anti-PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
Filed: 28 Jan 18
Utility
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
9 Nov 20
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
Filed: 9 Apr 20
Utility
Composition and method for the diagnosis and treatment of iron-related disorders
2 Nov 20
Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Filed: 1 Nov 18
Utility
Spiro-cyclic amine derivatives as S1P modulators
19 Oct 20
Axel Stoit, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Maria J. P. van Dongen, Nicolas J.-L. D. Leflemme, Adrian Hobson
Filed: 12 Nov 18
Utility
Systems and methods for tubing delivery
19 Oct 20
Adapters for a connector assembly for percutaneous tubing are provided.
Kellan William Babbs, Nolan Harrington Baird, III, Antonio Juan Belton, Sean Joel Corrigan, Charles Michael Galitz, Thomas Paul Grazier, Daniel Joseph Greene, Keith Aaron Grider, Thomas Joseph Huemann, Wayne Phillip Klingler, Michael Honsing Lau, Tomas Andrius Matusaitis
Filed: 9 Jul 15
Utility
Glucocorticoid receptor agonist and immunoconjugates thereof
14 Sep 20
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
Adrian Hobson, Michael McPherson, Wendy Waegell, Christian Goess, Axel Hernandez, Jr., Lu Wang, Lu Wang, Christopher C. Marvin, Ling C. Santora
Filed: 28 Nov 18
Utility
Use of inhibitors of Bruton's tyrosine kinase (Btk)
24 Aug 20
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
Filed: 20 Jan 20
Utility
Crystalline forms of a brutons tyrosine kinase inhibitor
24 Aug 20
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 31 Mar 20
Utility
Cylindrical pill dispenser and related methods of use
17 Aug 20
A pill dispenser includes an outer body for displaying one or more pills within the dispenser.
Lewis H. Sita, Bhimaprasad Medhal
Filed: 10 Dec 15
Utility
Systems and methods for tubing delivery
17 Aug 20
Connector assembly (FIG. 4a) includes a shell (210), a connector body (230), and a plug (250).
Kellan William Babbs, Nolan Harrington Baird, III, Antonio Juan Belton, Sean Joel Corrigan, Charles Michael Galitz, Thomas Paul Grazier, Daniel Joseph Greene, Keith Aaron Grider, Thomas Joseph Huemann, Wayne Phillip Klingler, Michael Honsing Lau, Tomas Andrius Matusaitis
Filed: 9 Jul 14
Utility
Medication packaging and dispensing system
10 Aug 20
A medication packaging and dispensing system is provided.
Lori Kim, Alexandra Breban-Lopez, Bhimaprasad Medhal, Dejan Bojicic, Guy Upchurch, John G. Finch, Lewis Sita
Filed: 13 Oct 16
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
3 Aug 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Ben Klünder, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer
Filed: 10 Feb 20
Utility
Carbidopa prodrug
3 Aug 20
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Philip R. Kym, Eric A. Voight
Filed: 4 Dec 18
Utility
Anti-PD-1 antibodies and their uses
3 Aug 20
The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
Filed: 21 Oct 19